As visceral adiposity decreases and insulin sensitivity improves, hepatic steatosis often diminishes, leading to normalization of elevated transaminases
The phase 2 trial data shows that fatigue rates varied more by titration speed than by final dose
Disclaimer: This article is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment
By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026
Precautions For adults only
Absolutely, GLP 1 & GIP therapy requires special care regarding its source, handling and the quality grade of the ingredients